Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/3/2025 | $20.00 | Hold | Jefferies |
| 1/3/2025 | Outperform → Peer Perform | Wolfe Research | |
| 10/10/2024 | $36.00 | Outperform | Raymond James |
| 10/9/2024 | $47.00 → $53.00 | Outperform | Oppenheimer |
| 3/28/2024 | $50.00 | Outperform | Oppenheimer |
| 3/13/2024 | $50.00 | Buy | Goldman |
| 2/20/2024 | $51.00 | Overweight | JP Morgan |
| 2/15/2024 | $55.00 | Outperform | Wolfe Research |
Jefferies initiated coverage of Immunovant Sciences with a rating of Hold and set a new price target of $20.00
Wolfe Research downgraded Immunovant Sciences from Outperform to Peer Perform
Raymond James resumed coverage of Immunovant Sciences with a rating of Outperform and set a new price target of $36.00
Pivotal study in MG met primary endpoint of change from baseline in MG-ADL in AChR+ population at 12 weeks, with a 5.6 point improvement in the higher dose arm (with 74% mean IgG reduction) and a 4.7 point improvement in the lower dose arm (with 64% mean IgG reduction)Initial CIDP results from Period 1, following standard of care washout, demonstrate a mean improvement in the adjusted INCAT disability score of 1.8 across batoclimab arms and an 84% responder rate in those patients who achieved an IgG lowering greater than 70%In both batoclimab studies, deeper IgG reductions correlated with better clinical outcomes across a range of assessments and timepointsINDs active for both MG and CIDP wi
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast Details The company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The l
8-K - Immunovant, Inc. (0001764013) (Filer)
144 - Immunovant, Inc. (0001764013) (Subject)
SCHEDULE 13G/A - Immunovant, Inc. (0001764013) (Subject)
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that it will host an investor webcast on Wednesday, March 19th at 8:00 a.m. ET to review results from its Phase 3 study of batoclimab in MG and initial results from its Phase 2b study in CIDP. Pete Salzmann, M.D., MBA, Chief Executive Officer of Immunovant, will be joined by Matt Gline, Chief Executive Officer of Roivant, for the call. Webcast DetailsThe company will host a webcast at 8:00 a.m. ET on Wednesday, March 19. Please click here to register for the event. The live webcast
Lead asset IMVT-1402 rapidly progressing with now six Investigational New Drug (IND) applications cleared and pivotal studies in Graves' disease (GD) and difficult-to-treat rheumatoid arthritis (D2T RA) now enrolling with 2.25ml autoinjector Additional results from batoclimab proof-of-concept study in GD, including 6-month treatment free remission data expected in summer 2025 Top line results of the batoclimab trial in myasthenia gravis (MG) and initial results from period 1 of batoclimab trial in chronic inflammatory demyelinating polyneuropathy (CIDP) expected by March 31, 2025 Pro forma cash balance of approximately $825 million as of December 31, 2024, including approximately $450 mil
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves' disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rheumatoid arthritis (RA), with potential best-in-class profile in difficult-to-treat (D2T) RA; initiation of potentially registrational trial to evaluate IMVT-1402 in D2T RA expected by March 31, 2025O
4 - Immunovant, Inc. (0001764013) (Issuer)
4 - Immunovant, Inc. (0001764013) (Issuer)
SC 13G/A - Immunovant, Inc. (0001764013) (Subject)
SC 13G/A - Immunovant, Inc. (0001764013) (Subject)
SC 13G - Immunovant, Inc. (0001764013) (Subject)
Ankyra is pleased to announce the appointment of Dr. Julia G. Butchko and Ms. Tara Withington to the Board of Directors effective September 25, 2024. They will both serve as independent board members and their appointment brings the total board composition to seven directors. "We are delighted to welcome Dr. Butchko and Ms. Withington to the Board", stated Tillman Gerngross, PhD, Chairman of the Ankyra Board of Directors. "These accomplished individuals bring a fresh perspective to Ankyra at a critical time in the company's growth." Howard L. Kaufman, MD, President and Chief Executive Officer at Ankyra added "I am especially enthusiastic about working with Dr. Butchko and Ms. Withington sin
Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, announced the appointment of Mark Levine as Chief Legal Officer. "We are extremely pleased to welcome Mark Levine as Immunovant's Chief Legal Officer," said Pete Salzmann, M.D., Chief Executive Officer. "Mark's broad legal experience at biopharmaceutical companies ranging from early-stage development through commercialization wil
Ms. Barnett brings a wealth of financial experience to ImmunovantExpands executive leadership team as Immunovant plans to return to the clinic across multiple indications NEW YORK, Sept. 15, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (NASDAQ:IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced the appointment of Renee Barnett, as Chief Financial Officer, effective October 4, 2021. "We are incredibly excited to have Renee Barnett join the Immunovant management team at this important time for our company," said Pete Salzmann, M.D., Chief Executive Officer. "Renee brings a deep understanding of drug developmen
4 - Immunovant, Inc. (0001764013) (Issuer)
4 - Immunovant, Inc. (0001764013) (Issuer)
4 - Immunovant, Inc. (0001764013) (Issuer)